Semax
Neuroprotection, BDNF & Cognitive Research
STRONG PRECLINICAL / LIMITED HUMAN EVIDENCE
NOT ESTABLISHED
NOT APPROVED
What Is Semax?
Semax is a synthetic seven-amino-acid peptide, or heptapeptide, with the sequence Met-Glu-His-Phe-Pro-Gly-Pro — MEHFPGP. It was developed from a fragment of adrenocorticotropic hormone (ACTH 4–7) combined with the tripeptide Pro-Gly-Pro. FDA identifies Semax as a heptapeptide and synthetic analog related to the ACTH 4–10 region.
Unlike full-length ACTH, Semax has primarily been investigated for neurological rather than adrenal effects. Research interest has included neuroprotection, cerebral ischemia and stroke, BDNF and neurotrophin signaling, learning and memory, attention, neuroplasticity, inflammatory responses after brain injury, cognitive recovery, pain pathways, and anxiety and mood-related mechanisms.
Important: Semax is not FDA-approved in the United States for stroke, cognitive enhancement, ADHD, memory improvement, neuroprotection, or any other therapeutic indication.
Why Are Researchers Interested?
Semax has generated interest because several experimental studies suggest that it may influence neurotrophic signaling—the molecular systems involved in neuronal survival, repair, and synaptic plasticity. Researchers have investigated effects involving:
Animal research has repeatedly demonstrated effects on BDNF-related pathways after intranasal Semax administration. There is also some human clinical literature involving ischemic stroke. However, much of the human evidence is older, originates predominantly from Russian clinical research, and does not meet the evidentiary standard of a modern U.S. Phase 1–3 drug-development program.
What The Research Suggests
Semax Can Influence BDNF in Animal Models
BDNF — brain-derived neurotrophic factor — is a protein involved in neuronal survival, synaptic plasticity, learning, and memory. In a rat study, intranasal Semax produced a rapid increase in BDNF protein in the basal forebrain.
Researchers also identified specific binding activity for Semax in brain-cell membranes, suggesting that Semax may interact with particular molecular targets rather than producing only a nonspecific peptide effect.
Semax Also Influences BDNF/TrkB Signaling in the Hippocampus
Another animal study found that a single intranasal dose of Semax increased BDNF protein, BDNF gene expression, TrkB gene expression, and TrkB receptor activation in the rat hippocampus. Researchers also observed improved performance on a conditioned-learning task.
This supports a plausible relationship between Semax and neuroplasticity-related signaling. However, increasing BDNF in a rat brain does not establish that Semax improves memory, intelligence, or cognition in humans.
Neurotrophin Gene Expression Has Been Studied After Ischemia
Animal research has also examined Semax after experimentally induced cerebral ischemia. Researchers found changes involving BDNF, NGF, TrkA, TrkB, TrkC, and other neurotrophin-related genes following Semax administration after experimentally induced brain ischemia.
These findings provide a scientific rationale for investigating Semax in stroke and brain-injury research. They do not, by themselves, establish clinical effectiveness.
Human Stroke Research Does Exist
Semax differs from some investigational peptides because it has been evaluated in people with ischemic stroke. An older controlled clinical study reported that adding Semax to standard intensive therapy during acute ischemic stroke was associated with faster improvement in certain neurological measures, particularly motor-related deficits.
Another publication examined proposed immunological mechanisms during acute ischemic stroke and reported changes in inflammatory mediators associated with Semax treatment.
Post-Stroke Rehabilitation Has Also Been Studied
A later study involving 110 people after ischemic stroke examined Semax during rehabilitation. Researchers reported increases in plasma BDNF and associations with improvements in Barthel Index scores and motor recovery.
This is meaningful human evidence. But it still requires context. The study does not establish that Semax prevents stroke, reverses brain damage, produces recovery in every stroke patient, is equivalent to an FDA-approved stroke therapy, or improves cognition in healthy people.
Preclinical Research Suggests Anti-Inflammatory Effects After Stroke
A 2021 study examining experimental cerebral ischemia found that Semax suppressed expression of several pro-inflammatory genes induced after reversible brain ischemia in rats. This adds another possible mechanism to Semax's proposed neuroprotective effects.
Again, this is preclinical research, not proof of clinical effectiveness in human stroke.
Evidence At A Glance
BDNF & Neurotrophin Signaling
Animal studies demonstrate effects involving BDNF, NGF, TrkB, and related neuroplasticity pathways.
Cerebral Ischemia / Stroke
Several Russian clinical studies report neurological or rehabilitation-related effects following ischemic stroke.
Memory & Cognitive Enhancement
Animal findings and mechanistic research exist, but robust controlled human nootropic trials are lacking.
ADHD
FDA's 2026 review did not identify adequate supporting literature for ADHD.
Alzheimer's / Dementia
No adequate clinical evidence establishes Semax as a treatment or prevention strategy for neurodegenerative disease.
Anti-Aging / Longevity
Semax is not an established anti-aging or lifespan-extension therapy.
Safety & Limitations
The biggest limitation surrounding Semax is that the available human safety data are incomplete. FDA's 2026 scientific review concluded that there was insufficient clinical information to adequately characterize the safety profile of Semax free base or Semax acetate. FDA also reported that it could not identify published human pharmacokinetic studies.
Intranasal Research Does Not Establish Injectable Safety
This distinction is particularly important. The published human Semax research reviewed by FDA involved primarily intranasal administration. FDA found no safety data for Semax administered by the proposed subcutaneous route.
Therefore, evidence from intranasal Semax should not automatically be used to establish the safety of subcutaneous injections, intramuscular injections, intravenous administration, or other compounded formulations. Different routes may produce different exposure, immune responses, and safety profiles.
Immunogenicity Is an Unresolved Concern
FDA has identified concerns involving peptide aggregation, peptide-related impurities, manufacturing variability, product characterization, and potential immunogenicity. FDA's 2026 review states that no adequate clinical studies assessing Semax immunogenicity were identified and that available information is insufficient to conclude that Semax free base or acetate does not present these risks.
FDA's current safety resource similarly states that compounded Semax may pose an immunogenicity risk for certain routes because of aggregation and peptide-related impurities.
Possible Effects on Blood Clotting Require More Research
FDA identified older research suggesting antithrombotic or anticoagulant activity associated with Semax. Because of this, FDA raised a potential concern about bleeding risk in people who already have an increased bleeding risk, take anticoagulants, take antiplatelet drugs, or use other medications affecting coagulation.
This does not establish that Semax routinely causes clinically significant bleeding. It means the issue has not been adequately resolved.
Dopamine-Related Findings Also Require Caution
FDA's 2026 review noted preclinical research in which Semax potentiated amphetamine-related dopamine release in the rat striatum. FDA identified this as a reason why further investigation of abuse potential and neurological safety would be appropriate.
This does not establish that Semax is addictive. It demonstrates that its neuropharmacology is more complex than simply describing it as a benign “brain peptide.”
Regulatory Status
No. FDA states that neither Semax free base nor Semax acetate is a component of an FDA-approved drug. Semax is therefore not FDA-approved in the United States for stroke, cerebral ischemia, memory enhancement, cognitive enhancement, ADHD, Alzheimer's disease, dementia, anxiety, depression, migraine, trigeminal neuralgia, neuroprotection, or general wellness.
Semax does have a different regulatory history internationally. FDA's 2026 review notes that Semax is registered as a drug in Russia and available there as nasal drops. That foreign regulatory status does not constitute FDA approval in the United States.
This area changed significantly in 2026. FDA evaluated Semax free base and Semax acetate for potential inclusion on the Section 503A Bulks List, examining proposed uses involving cerebral ischemia, migraine, and trigeminal neuralgia, and evaluating both intranasal and proposed subcutaneous formulations. FDA's scientific evaluation concluded that the available evidence weighed against placing Semax free base or Semax acetate on the 503A Bulks List.
The Pharmacy Compounding Advisory Committee formally considered Semax-related substances on July 24, 2026. FDA also explains that its final regulatory determination occurs only after the advisory-committee process and completion of FDA's review.
Is Semax FDA-Approved?
No. FDA states that neither Semax free base nor Semax acetate is a component of an FDA-approved drug. Semax is therefore not FDA-approved in the United States for stroke, cerebral ischemia, memory enhancement, cognitive enhancement, ADHD, Alzheimer's disease, dementia, anxiety, depression, migraine, trigeminal neuralgia, neuroprotection, or general wellness.
Semax does have a different regulatory history internationally. FDA's 2026 review notes that Semax is registered as a drug in Russia and available there as nasal drops. That foreign regulatory status does not constitute FDA approval in the United States.
What About Compounding?
This area changed significantly in 2026. FDA evaluated Semax free base and Semax acetate for potential inclusion on the Section 503A Bulks List, examining proposed uses involving cerebral ischemia, migraine, and trigeminal neuralgia, and evaluating both intranasal and proposed subcutaneous formulations. FDA's scientific evaluation concluded that the available evidence weighed against placing Semax free base or Semax acetate on the 503A Bulks List.
FDA identified concerns including incomplete characterization of the bulk substances, inconsistent naming, limited human safety information, lack of human pharmacokinetic data, no clinical safety evidence for subcutaneous administration, potential immunogenicity, peptide aggregation and impurities, and uncertain evidence of effectiveness.
Pharmacy Compounding Advisory Committee Consideration
The Pharmacy Compounding Advisory Committee formally considered Semax-related substances on July 24, 2026. FDA also explains that its final regulatory determination occurs only after the advisory-committee process and completion of FDA's review.
Regulatory Status: Not FDA-Approved — Semax is an investigational neuroactive peptide with preclinical neuroprotection research and limited human clinical research involving cerebral ischemia and stroke. Semax is not FDA-approved in the United States for stroke, cognitive enhancement, ADHD, memory improvement, or any other therapeutic indication. In 2026, FDA evaluated Semax free base and Semax acetate for the Section 503A Bulks List and concluded that the available evidence weighed against inclusion. Future regulatory status cannot be predicted.
Semax vs. Selank
Semax and Selank are often marketed together as “nootropic peptides,” but they are different molecules with different biological histories and research profiles. Evidence demonstrating a Selank effect should not be attributed to Semax, and vice versa.
Semax
Derived from an ACTH-related peptide sequence (Met-Glu-His-Phe-Pro-Gly-Pro). Research emphasis includes neuroprotection, cerebral ischemia, BDNF, NGF, neuroplasticity, and memory and cognition.
Selank
Derived from tuftsin-related peptide research (Thr-Lys-Pro-Arg-Pro-Gly-Pro). Research emphasis includes anxiety, stress, GABA signaling, enkephalin metabolism, and cognitive effects.
ACTH
Adrenocorticotropic hormone is a much larger naturally occurring hormone produced by the pituitary gland. Its best-established function is stimulating the adrenal glands to produce cortisol. Semax was developed from a small ACTH-related sequence but should not be described as equivalent to ACTH.
Why the Difference Matters: Semax's neurological research involves mechanisms that appear substantially different from the classical adrenal-hormone effects of intact ACTH. Semax and Selank are not interchangeable substances.
Research & Publications
FDA Scientific Review — Semax Free Base & Semax Acetate
U.S. Food and Drug Administration — May/July 2026
FDA's comprehensive evaluation of Semax chemistry, proposed compounded products, cerebral ischemia, migraine, trigeminal neuralgia, safety, human evidence, immunogenicity, intranasal and subcutaneous administration, and Section 503A considerations.
View FDA Semax Scientific ReviewFDA Pharmacy Compounding Advisory Committee — Semax
U.S. Food and Drug Administration — July 24, 2026
Official FDA meeting materials concerning Semax free base and Semax acetate and their consideration under Section 503A.
View FDA Advisory Committee MaterialsSemax, BDNF & the Basal Forebrain
Journal of Neurochemistry — 2006
Animal research found that intranasal Semax increased BDNF protein concentrations in the rat basal forebrain and identified specific Semax-binding activity.
View on PubMedSemax, BDNF & TrkB in the Hippocampus
Brain Research — 2006
Research found that Semax increased BDNF expression and TrkB signaling in rat hippocampus while affecting conditioned learning behavior.
View on PubMedSemax & Neurotrophin Gene Expression
Animal Research — 2007
Researchers examined BDNF and NGF gene expression after intranasal Semax and reported significant changes in rat hippocampus.
View on PubMedSemax in Acute Ischemic Stroke
Controlled Human Clinical Research
A clinical and electrophysiological study investigated Semax as part of treatment for acute ischemic stroke and reported differences in neurological recovery.
View on PubMedMechanisms of Semax During Acute Ischemic Stroke
Human Clinical Research
Researchers examined inflammatory and immunological mechanisms potentially associated with Semax during acute ischemic stroke.
View on PubMedSemax During Post-Stroke Rehabilitation
Human Clinical Research — 2018
A study involving 110 people after ischemic stroke evaluated Semax, plasma BDNF, motor recovery, and Barthel Index outcomes during rehabilitation.
View on PubMedSemax & Inflammatory Gene Expression After Brain Ischemia
Molecular Biology — 2021
Animal research found that Semax suppressed several pro-inflammatory mRNA responses induced by reversible cerebral ischemia.
View on PubMedSemax & Experimental Cerebral Infarction
Bulletin of Experimental Biology and Medicine
Animal research reported neuroprotective and anti-amnesic effects following experimentally induced cerebral ischemia.
View on PubMedFDA — Current Compounding Safety Concerns for Semax
U.S. Food and Drug Administration — Current 2026 Resource
FDA identifies potential immunogenicity concerns involving compounded Semax because of aggregation and peptide-related impurities.
View FDA Semax Safety InformationSemax is an experimental neuroactive peptide with a substantial preclinical research history involving BDNF, neurotrophin signaling, neuroinflammation, learning, and cerebral ischemia. Unlike many experimental peptides, Semax also has some published human clinical research, particularly involving ischemic stroke and neurological rehabilitation.
However, the human evidence remains limited, largely concentrated within Russian research programs, and substantially less developed than the evidence required for FDA approval in the United States. Animal BDNF findings should not be interpreted as proof that Semax improves cognition in healthy people. Stroke studies should not be generalized into claims that Semax prevents strokes, reverses neurological injury, or treats Alzheimer's disease. Claims involving ADHD, memory enhancement, anxiety, depression, or general nootropic performance also remain inadequately established.
Semax is not FDA-approved in the United States for any therapeutic indication, and FDA's 2026 review identified substantial unresolved questions involving effectiveness, product characterization, immunogenicity, long-term human safety, and subcutaneous administration. This page is provided for educational purposes only. Semax is not offered for sale, prescription, or distribution through this website.